Summary Advanced glycation end-product-formation is thought to play a role in the development of diabetic angiopathy. By altering the structure of different extracellular matrix components advanced glycation endproducts might affect vascular and glomerular permeability. In this study we investigated the effect of treatment with an inhibitor of advanced glycation endproduct-formation, aminoguanidine, on vascular permeability and the development of albuminuria in streptozotocin-induced diabetic rats. Male Wistar Rp rats were randomized into a control group, a diabetic group, and an aminoguanidine-treated diabetic group. After 8 weeks, 24-h urine collections were taken and rats were implanted with an arterial and a venous catheter. Mean arterial blood pressure was determined by intra-arterial measurement. Regional albumin clearances were assessed in the eye, ileum, lung, skeletal muscle and skin using an isotope technique. Mean arterial pressure in the diabetic group was significantly lower in the control and aminoguanidine-treated groups (p < 0.02). Regional albumin clearances were significantly increased in all tissues of diabetic rats compared to control rats (p < 0.05). Aminoguanidine treatment of diabetic rats resulted in a significant decrease of regional albumin clearance in all tissues except the lung (p < 0.05, lung p = 0.07). The development of albuminuria in diabetic rats however, was not affected by aminoguanidine. [Diabetologia (1994) 37:
The formation of advanced glycation end-products (AGEs) on long-lived macromolecules has been implicated in the aetiology of diabetic angiopathy. Numerous reports have shown that AGE-formation can alter the function of several systems that are involved in cardiovascular homeostasis [1] .
Extracellular matrix components such as type IV collagen and laminin undergo marked structural changes following glycation [2, 3] . The observed alterations might influence the interaction of these components with other basement membrane elements such as heparan sulphate proteoglycan (HS-PG). Alterations in the density of HS-PG in glomerular basement membrane and the vascular wall are thought to play a role in the development of both glomerular and systemic permeability changes in diabetes [4, 5] . Increases in vascular permeability and increase in urinary albumin excretion have been shown to develop simultaneously in both clinical and experimental diabetes [6] [7] [8] [9] .
Aminoguanidine, a nucleophilic hydrazine compound, prevents the formation of AGEs [10] . This drug has been shown to decrease albuminuria in spontaneously hypertensive diabetic rats [11] . In addition, experiments in a skin-chamber model suggest that it can reduce the increased vascular permeability induced by hyperglycaemia [12] . We hypothesized that a beneficial effect of aminoguanidine would also imply reduction of increased regional albumin clearance in other organs. Therefore, in this study we assessed the effects of aminoguanidine treatment on blood pressure, albuminuria In previous studies we and others have shown that 8 weeks of experimental diabetes is sufficient for rats to develop serious vascular dysfunction, which closely resembles the disturbances observed in human diabetes [8, [13] [14] [15] . Moreover, this diabetes duration is characterized by significant accumulation of AGEs [16] .
rectly in this study. One day after surgery, the arterial catheter was connected to a low volume displacement pressure transducer (CP-01, Century Technology Company, Inglewood, Calif., USA). The signal was recorded on a Grass 7D polygraph (Grass Instruments, Quincy, Mass., USA). Low-pass filtering of the signal yielded mean arterial pressure. During the measurements rats were allowed to move freely in their cages. Actual blood pressure measurements were performed following a 30-min stabilization period.
Materials and methods

Animals
Male Wistar Rp rats (TNO-REPGO, Rijswijk, The Netherlands) were used. Rats were randomized into a control group (n = 8), a diabetic group (n = 8) and an aminoguanidine-treated diabetic group (n = 8). Diabetes was induced at the age of 6-8weeks by i.p. injection of 70 mg/kg streptozotocin (Sigma, St. Louis, Mo., USA) in citrate buffer (pH 4.5). Control rats received an i.p. injection of the vehicle. Development of diabetes was verified by blood glucose measurements (hexokinase method), 3 days after streptozotocin administration. Only rats with blood glucose levels above 15 mmol/l were included in the study. Aminoguanidine-hemisulphate (Sigma) was administered in daily doses of 50 mg/kg by s. c. injection. Treatment was started immediately after diabetes induction and continued for a period of 7 weeks. Urinary albumin excretion was measured in the original group of 24 rats and in an additional 18 rats, randomized and treated as described above.
Surgery
Two days prior to the extravasation study rats were anaesthetized with ether, and a polyethylene (PE-10)/vinyl catheter was implanted into the abdominal aorta through the left femoral artery. The caval vein was cannulated with a similar catheter through the left femoral vein. Both catheters were filled with saline, dosed with metal plugs and exteriorized in the neck. The procedure was performed under aseptic conditions.
Blood pressure measurements
Since it has been shown that blood pressure data obtained with the indirect tall-cuff method are unreliable and artificially elevated in diabetic rats [17, 18] , blood pressure was measured di-
Determination of urinary albumin excretion
Three days before the extravasation study, rats were placed in metabolic cages in order to collect 24-h urine samples. Urinary production was determined and urine samples were frozen until further analysis (within i week). Urinary albumin content was measured by rocket immunoelectrophoresis [19] using a goat anti-rat albumin antibody (Nordic Immunological Laboratories, Tilburg, The Netherlands). The urine samples (diluted 1:5 or 1:10) and a rat albumin standard (Nordic) were added in 2 gl quantities to agarose gel plates containing 1% antibody. Rocket heights were measured and compared with the standard curve. The lowest detection limit of the assay was 5 gg/ml.
Determination of regional albumin permeation
Regional albumin permeation was determined in the eye, ileum, skin, forearm skeletal muscle and lung using a double label isotope technique. We used a slightly modified version of previously published methods [20] [21] [22] . In brief, 0. HSA is used as marker for the intravascular space. The circulation time of 10 min for the permeating tracer has been shown to be sufficient to obtain a significant albumin extravasation, as albumin disappearance consists of two phases, a rapid one from 0-10 min after injection and a slower one from 10-60 min, both accounting for 50 % of the albumin el- 
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Urinary albumin excretion rate (Ualb V) 8 weeks after start of the study in control rats (C, n = 14), diabetic rats (D, n = 14) and amino guanidine-treated diabetic rats (AG, n = 14). Individual Ua~bV values are given plus the median value for each group. Significantly different from values in control rats, *p < 0.01 flux per h [23, 24] . In previous studies, both phases of albumin disappearance were shown to be increased in diabetic rats [25] . ferences in body weight nor blood glucose levels could be observed. Body weight and blood glucose levels of the additional 18 rats that were used to determine urinary albumin excretion are also given in Table 1 .
Statistical analysis
All values are given as mean + SD, or as median with range when not normally distributed. Groups were compared with analysis of variance (ANOVA) with the Sidak post-hoc test for multiple comparisons or with the Kruskal Walfis test when not normally distributed (Crunch4 Manual, Crunch Software Corporation, Oakland, Calif., USA).
Blood pressure
Mean arterial blood pressure was significantly lower in diabetic rats compared to control rats (p <0.02, Table 1 ), while rats treated with aminoguanidine had mean arterial pressures comparable to those of control rats.
Results
General characteristics
Body weight was lower in both groups of diabetic rats compared to control rats (p < 0.0001), while blood glucose levels were significantly elevated in the diabetic groups (p < 0.0001, Table 1 ). Between untreated diabetic rats and aminoguanidine-treated rats neither dif-
Urinary albumin excretion
Urinary albumin excretion rate (U~bV) was significantly elevated in diabetic rats compared to control rats, Fig. 1 ). Aminoguanidine treatment did not affect U~bV in diabetic rats. In the aminoguanidine-treated group, the variation in Ua~bV values was comparable to that of untreated diabetic rats (median 10.1 [1.5-112.7] , p < 0.001 compared to control rats).
Effects on regional albumin permeation
In all organs regional albumin clearance was significantly increased in diabetic rats compared to control rats (Fig. 2) . Diabetic rats treated with aminoguanidine had albumin clearances that were significantly lower than those of untreated rats and not different from values of control rats in all tissues, except the lung (p = 0.07 compared to diabetic rats).
Discussion
This study reveals a marked effect of long-term treatment with aminoguanidine, an inhibitor of AGE-formation, on increased regional albumin clearance in diabetic rats. However, no effects on urinary albumin excretion were observed. In addition we found a slight blood pressure elevating effect of aminoguanidine. The observed effects of aminoguanidine on regional albumin clearance are in accordance with the report of Corbett et al. [12] who showed a normalization of permeability induced by hyperglycaemia in skin-chamber granulation tissue. They suggest that aminoguanidine normalizes increased vascular permeability by correcting the diabetes induced nitric oxide (NO)-overproduction leading to increased flow, since other inhibitors of NO-formation such as NG-Monomethyl-L-arginine (L-NMMA) had similar effects. In their study aminoguanidine administration also slightly raised blood pressure, although about 40 times less effectively than L-NMMA. Very recently, Tilton et al. [26] showed that methylguanidine, a compound with a comparable NOsynthase inhibiting action as aminoguanidine but no effects on AGE-formation, also prevented vascular dysfunction in experimental diabetes. However, we measured increases in vascular permeability in vascular beds, such as skeletal muscle and skin, to which blood flow is decreased in experimental diabetes [27] , which makes the concept of NO-overproduction resulting in increased flow and increased vascular permeability, not generally applicable. In addition, in another study we have observed a significant increase in vascular elasticity in diabetic rats following long-term treatment with aminoguanidine which could not be attributed to NOdependent alterations in vascular tone [28] , indicating that there are beneficial effects of aminoguanidine on vascular dysfunction in diabetes that are definitely not related to its NO-inhibiting actions. Since we have not quantified effects of aminoguanidine treatment in nondiabetic rats, the possibility that aminoguanidine reduces albumin clearance per se, whether increased or not cannot be ruled out. On the other hand, Kihara et al. [29] have shown that aminoguanidine treatment did not 13 affect the unaltered albumin clearance of sciatic nerve tissue from diabetic rats.
Increased urinary albumin excretion was not affected by aminoguanidine in this study. This is in contrast to the results in spontaneously hypertensivediabetic rats [11] and in diabetic rats [30] . In both studies rats were treated for a significantly longer period (24-32 weeks) which might explain the difference between our results and these studies. In addition, one study does not report effects on blood pressure [30] whereas the other refers to blood pressures that were determined by indirect tail-cuff plethysmography, and therefore cannot be interpreted properly. There is strong evidence that this method produces artificially elevated blood pressure recordings, as a result of either structural or haemodynamic alterations in the tail of diabetic rats [17, 18] . In our own laboratory we also observed differences between direct intra-arterial blood pressure measurements and tail-cuff recordings. Taking into account the observed rise in mean arterial pressure following aminoguanidine treatment, one could speculate that effects on urinary albumin excretion are masked by an increase in blood pressure, although we did not find any relationship between blood pressure and albuminuria in our animals. Urinary albumin excretion is certainly influenced by arterial pressure as has been demonstrated by the marked effects of different antihypertensive regimens on urinary albumin excretion in both experimental and clinical diabetes [31, 32] .
The observed disparity in effects of aminoguanidine on regional albumin clearance and urinary albumin excretion might also indicate that the mechanisms involved in the development of systemic permeability changes and albuminuria are, at least partially, distinct. The fact that increased vascular permeability, assessed by measuring the transcapillary escape rate of albumin, only develops in diabetic patients with some degree of albuminuria [6] together with the tremendous increase in cardiovascular disease that is associated with the development of albuminuria [33] , has led to the hypothesis that albuminuria is a marker of widespread vascular damage [7] . A decreased content of HS-PG, as a result of AGE-formation on basement membrane components [1] or a genetically determined defect in HS-PG regulation [34] , has been proposed as one of the mechanisms responsible for both vascular and glomerular damage. Using our results, one can only speculate as to why and how aminoguanidine normalizes increased vascular permeability in diabetic rats without affecting albuminuria. However, in our opinion, in the kidney, haemodynamic changes which are perhaps not modified by aminoguanidine, play a more important role than in other tissues. It is important in this respect to remember that glomerular capillary pressure is several times higher than capillary pressures in other tissues. In previous studies it has been shown that the albuminuria in experimental diabetes is particularly sensitive to angiotensin converting enzyme-inhibitors [13, 31] . This would support the concept that angiotensin II-dependent intrarenal haemodynamic mechanisms contribute to the control of urinary albumin excretion.
In conclusion, we have shown that aminoguanidine treatment normalizes increased vascular permeability in diabetic rats, while in this study no effects of aminoguanidine on albuminuria were observed. The effects of aminoguanidine on vessel wall permeability suggest that this drug can protect the vascular system in (experimental) diabetes.
